1
|
UHRF1 Induces Metastasis in Thyroid Cancer. JOURNAL OF ONCOLOGY 2022; 2022:7716427. [PMID: 35996525 PMCID: PMC9392644 DOI: 10.1155/2022/7716427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 06/12/2022] [Accepted: 06/29/2022] [Indexed: 12/01/2022]
Abstract
Background Ubiquitin-like with PHD and ring-finger domain 1 (UHRF1) has been defined as an oncogene in tumor cells. However, the role of UHRF1 in mediating metastasis in thyroid cancer remains unexplored. In this study, we aimed to investigate the metastatic function and the potential mechanisms of UHRF1 in thyroid cancer. Methods Transwell assays were used to detect the metastatic capability of thyroid cancer. Dual-luciferase reporter assays were applied to examine the activation of transcription factors. Coimmunoprecipitation assays and immunofluorescence staining assays were used to elucidate the potential mechanisms of UHRF1 in promoting the metastasis of thyroid cancer. Results In this study, we found that overexpression of UHRF1 promoted the metastasis of papillary thyroid cancer cells, and suppression of UHRF1 decreased the metastasis of anaplastic thyroid cancer cells. Regarding the signaling pathway in regulating metastasis, UHRF1 directly combined and activated the transcription factor c-Jun/AP-1 in the nucleus, subsequently increasing the transcription of IL-6 and MIF. Conclusion Our results suggest that UHRF1 could induce the metastasis of thyroid cancer, and the potential signaling pathway might be that UHRF1 activates c-Jun/AP-1 to increase the expression of IL-6 and MIF. These findings provide a novel mechanism of UHRF1 and illustrate that UHRF1/AP-1 complex could be a potential therapeutic target for patients with thyroid cancer.
Collapse
|
2
|
Autenshlyus A, Arkhipov S, Mikhaylova E, Marinkin I, Arkhipova V, Varaksin N, Vavilin V, Lyahovich V. Analyzing the relationship between the cytokine profile of invasive breast carcinoma, its histopathological characteristics and metastasis to regional lymph nodes. Sci Rep 2021; 11:11359. [PMID: 34059727 PMCID: PMC8166970 DOI: 10.1038/s41598-021-90930-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 05/17/2021] [Indexed: 02/07/2023] Open
Abstract
This study was aimed at analyzing the relations of metastasis to regional lymph nodes (RLNs) with histopathological indicators of invasive breast carcinoma of no special type (IC-NST) and its cytokine profile. Enzyme-linked immunosorbent assays were performed to determine concentrations of IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-1β, IL-1Ra, TNF-α, IFN-γ, G-CSF, GM-CSF, VEGF-A, and MCP-1 in the culture supernatant of IC-NST samples from 48 female patients. Histopathological indicators (degree of tumor cell differentiation, mitoses, and others) and ER, PR, Her2/neu, Ki-67, and CD34 expression levels were determined. By means of three types of neural network models, it was shown that for different parameters of the output layer, different groups of parameters are involved that have predictive value regarding metastasis to RLNs. As a result of multi-dimensional cluster analysis, three clusters were formed with different cytokines profiles of IC-NST. Different correlations between indicators of cytokine production by IC-NST and its histopathological parameters were revealed in groups with different cytokine profiles. It was shown that at simultaneous evaluation of the production of even two cytokines, the importance of which relationship with metastasis was revealed by neural network modeling, can increase the probability of determining the presence of metastasis in the RLNs.
Collapse
Affiliation(s)
- Alexander Autenshlyus
- Department of Scientific Work, Central Research Laboratory, Laboratory of Immunohistochemistry Biochemistry and Pharmacology, Novosibirsk State Medical University, Krasny Prospect 52, Novosibirsk, 630091, Russian Federation.,Institute of Molecular Biology and Biophysics - subdivision of FRC FTM, Novosibirsk, Russia
| | - Sergey Arkhipov
- Department of Scientific Work, Central Research Laboratory, Laboratory of Immunohistochemistry Biochemistry and Pharmacology, Novosibirsk State Medical University, Krasny Prospect 52, Novosibirsk, 630091, Russian Federation. .,Institute of Molecular Biology and Biophysics - subdivision of FRC FTM, Novosibirsk, Russia.
| | - Elena Mikhaylova
- Department of Scientific Work, Central Research Laboratory, Laboratory of Immunohistochemistry Biochemistry and Pharmacology, Novosibirsk State Medical University, Krasny Prospect 52, Novosibirsk, 630091, Russian Federation.,Institute of Molecular Biology and Biophysics - subdivision of FRC FTM, Novosibirsk, Russia
| | - Igor Marinkin
- Department of Scientific Work, Central Research Laboratory, Laboratory of Immunohistochemistry Biochemistry and Pharmacology, Novosibirsk State Medical University, Krasny Prospect 52, Novosibirsk, 630091, Russian Federation
| | - Valentina Arkhipova
- Department of Scientific Work, Central Research Laboratory, Laboratory of Immunohistochemistry Biochemistry and Pharmacology, Novosibirsk State Medical University, Krasny Prospect 52, Novosibirsk, 630091, Russian Federation
| | | | - Valentin Vavilin
- Institute of Molecular Biology and Biophysics - subdivision of FRC FTM, Novosibirsk, Russia
| | - Vyacheslav Lyahovich
- Institute of Molecular Biology and Biophysics - subdivision of FRC FTM, Novosibirsk, Russia
| |
Collapse
|